| abstract |
This disclosure discloses compounds that form covalent bonds with brutonyl tyrosine kinase (BTK). A method for producing a compound is disclosed. Also disclosed are pharmaceutical compositions comprising such compounds. Methods for using BTK inhibitors, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, xenogenic immune diseases or conditions, cancers including lymphomas, and inflammatory diseases or conditions are disclosed. (I) |